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Abstract
Background: The t(9;22)(q34;q11) generating the BCR/ABL1 fusion gene represents the cytogenetic hallmark of
chronic myeloid leukemia (CML). About 5–10% of CML cases show variant translocations with the involvement of
other chromosomes in addition to chromosomes 9 and 22. The molecular bases of biological differences between
CML patients with classic and variant t(9;22) have never been clarified.
Findings: In this study, we performed gene expression microarray analysis to compare CML patients bearing variant
rearrangements and those with classic t(9;22)(q34;q11). We identified 59 differentially expressed genes significantly
associated with the two analyzed groups. The role of specific candidate genes such as TRIB1 (tribbles homolog 1),
PTK2B (protein tyrosine kinase 2 beta), and C5AR1 (complement component 5a receptor 1) is discussed.
Conclusions: Our results reveal that in CML cases with variant t(9;22) there is an enhancement of the MAPK
pathway deregulation and show that kinases are a common target of molecular alterations in hematological
disorders.
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Background
Chronic myeloid leukemia (CML) is a myeloprolife-
rative disorder derived from hematopoietic stem cell
transformation and characterized by heterogeneous bio-
logical and clinical features. The CML molecular marker
is BCR/ABL1 fusion gene generation as a consequence
of a reciprocal t(9;22)(q34;q11) [1,2]. In most cases, the
Philadelphia (Ph) chromosome is cytogenetically detect-
able but about 5–10% of CML patients show variant t
(9;22)(q34;q11) rearrangements with the involvement of
additional chromosomes [3,4]. In these cases the BCR/
ABL1 fusion gene can be revealed by Fluorescence in
situ hybridization (FISH) or reverse transcriptase-
polymerase chain reaction [5]. The occurrence of gen-
omic microdeletions proximally to ABL1 or distally to
BCR has been reported in CML cases with variant trans-
locations with a greater frequency (30-40%) than in
cases with classic t(9;22) (10-18%) [6,7]. The prognostic
significance of variant t(9;22) was unclear and debated
in the pre-imatinib era, whereas recent studies of large
CML series have reported that the presence of variant
translocations has no impact on the cytogenetic and
molecular response or on prognosis [6,8]. However, the
molecular bases of biological differences between CML
patients with classic and variant t(9;22) have never been
elucidated.
In this study, we performed gene expression profiling
(GEP) by microarrays to identify a signature discrimina-
ting CML patients bearing variant rearrangements from
those with classic t(9;22)(q34;q11). A list of 59 genes
was found to be significantly associated with the two an-
alyzed groups showing a differential expression. We ap-
plied network analysis to evaluate potential pathways
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involved in CML heterogeneity. An overall deregulation
of genes encoding for protein kinases and involved in cru-
cial cellular pathways such as MAPK (mitogen-activated
protein kinase) signaling was found, unveiling the bio-
logical basis of differences in the CML patients subgroup
with variant rearrangements.
Findings
Banding and molecular cytogenetic analyses allowed
the identifications of 12 CML cases with classic t(9;22) and
8 cases with variant translocations (Additional file 1,
Additional file 2). The BCR/ABL1 fusion analysis revealed
the occurrence of b2a2 or b3a2 junctions in 10 (7 with classic
Figure 1 Hierarchical genes clustering in CML with classic (12 cases) and variant (8 cases) t(9;22) showing a 59-gene signature. Each
row represents a single gene; green indicates differentially decreased expression of each gene in CML patient samples with variant t(9;22)
compared with classic t(9;22) and red indicates differentially increased expression. The more saturated the color, the greater the degree of
differential expression. N/A indicates genomic sequences not yet annotated.
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and 3 with variant rearrangement) and in 10 (5 with classic
and 5 with variant rearrangement) cases, respectively. All
these patients were selected for further GEP analysis by
oligonucleotide microarrays (Additional file 2). A set of 59
genes was identified as differently expressed in CML cases
with variant t(9;22) rearrangements. All deregulated genes
showed amore than 2 fold expression change; results of gene
expression analysis indicated that 45 out of 59 differentially
expressed genes were up-regulated whereas 14 were down-
regulated (Figure 1; Additional file 3).
Figure 2 Deregulated genes in CML cases with variant t(9;22). (A) “Hematological System Development and Function, Tissue Morphology,
Cellular Development” network deriving from GEP in CML cases with variant t(9;22). Both direct (solid lines) and indirect (dashed lines)
interactions among genes are shown. Colored symbols correspond to genes included in our set of differentially expressed genes (red = upregulated and
green = downregulated). (B) The involvement of TRIB1, PTK2B and C5AR1 kinases in the RAS/MAPK pathway downstream to the BCR/ABL oncoprotein.
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Upregulation of kinases genes
Querying the Database for Annotation, Visualization and
Integrated Discovery (DAVID) showed that the enhanced
biological process in our gene set involved the intracellular
protein kinases cascade, a series of reactions in which a
signal is passed within the cell by sequential protein
phosphorylation. This enhancement was significant (p =
0.003) and associated to a value of 7.6. In detail, the
kinases list included 5 genes: TRIB1 (tribbles homolog 1),
STK17B (serine/threonine kinase 17b), PTK2B (PTK2B
protein tyrosine kinase 2 beta), C5AR1 (complement com-
ponent 5a receptor 1) and ZFP36 (zinc finger protein 36,
C3H type, homolog). Interestingly, TRIB1 resulted one of
the highest expressed genes showing a 2.9-fold change in
GEP experiments. The upregulation of all 5 kinases was
confirmed by quantitative real-time polymerase chain re-
action experiments (qRT-PCR) analysis, with statistically
significant expression levels ranging from 2.20 to 8.02.
Involvement of kinases in the RAS/MAPK pathway
Further Ingenuity Pathways Analysis (IPA) analysis
yielded strong indications that 19 out of 59 dysregulated
genes from our dataset are involved in the “Haema-
tological System Development and Function, Tissue
Morphology, Cellular Development” network (Figure 2A).
A central role in this network is played by several pro-
teins that are known to be activated in BCR/ABL1 cells,
namely ERK1/2 (extracellular signal-regulated kinases),
p38MAPK (p38 mitogen-activated protein kinase), JNK
(c-Jun N-terminal kinase), and cell cycle regulator AKT
(RAC-alpha serine/threonine-protein kinase) that have a
key function in multiple cellular processes such as apop-
tosis and cell proliferation (Figure 2A). In this respect,
three main cellular processes are dysregulated by the
BCR/ABL oncoprotein: RAS/MAPK which induces acti-
vation of proliferation, the PI3K (phosphatidylinositol-3
kinase)/AKT that activates apoptosis, and JAK/STAT
which leads to an increased transcriptional activity [9].
Noteworthy, the upregulated kinase genes, previously
revealed by DAVID analysis, are also enclosed in the net-
work identified by IPA and establish direct or indirect
interactions with other network components (Figure 2A).
Moreover, TRIB1, PTK2B and C5AR1 kinases are in-
volved in the regulation of the RAS/MAPK pathway
(Figure 2B) [10-12]. TRIB1 is a signaling regulatory pro-
tein involved in leukemogenesis by regulating cellular
proliferation and myeloid differentiation [10]. This pro-
tein binds to the ‘middle layer’ of kinases in the MAPK
network, MAPKK (mitogen activated protein kinase
kinase), and acts as an adaptor between the MAPKK path-
way and C⁄EBPα (CCAAT⁄enhancer binding protein alpha).
In fact, TRIB1 interacts with MEK1 (mitogen-activated
ERK kinase 1) and MKK4 (MAP kinase kinase 4) and
enhances phosphorylation of ERK1⁄2, promoting cell
proliferation and suppressing apoptosis. ERK1/2 phospho-
rylation is required for C⁄EBPα degradation and the activa-
tion of hnRNP-E2 (poly(rC) binding protein 2), a C⁄EBPα
repressor (Figure 2B) [10]. Moreover, PTK2B is a proline–
rich kinase involved in calcium induced regulation of ion
channel and activation of the MAPK signaling pathway by
stimulating JNK and ERK1/2 activity (Figure 2B) [11].
PTK2B is a member of the FAK tyrosine kinases family that
could be activated by BCR-ABL causing an aberrant cell ad-
hesion. C5AR1 is a member of the rhodopsin family of G
protein-coupled receptors and is also the receptor of C5a
anaphylatoxin, a strong proinflammatory mediator. It has
been recently demonstrated that C5a binding to C5aR on
human intestinal epithelial cells activates ERK1/2 and AKT
phosphorylation [12].
To date several profiling studies in CML have been
reported focusing mainly on predicting response to
imatinib therapy and identifying a gene-specific signature
for different stages of the disease [13,14]. Our GEP ana-
lysis performed on CML cases with variant t(9;22) may
improve the understanding of the biological mechanisms
at the basis of the CML heterogeneity. Overall, our results
reveal that in CML cases with variant t(9;22) there is an
enhancement of the MAPK pathway deregulation already
known to underlie the CML pathogenesis and point out
the role of interesting candidate genes, such as TRIB1,
PTK2B, and C5AR1. These findings show that kinases are
a common target of molecular alterations in hematological
disorders and reinforce the idea that a perturbed action of
signal transduction pathways is one of the hallmarks of
cancer.
Additional files
Additional file 1: Table S1. Molecular cytogenetic characteristics of
CML cases with variant t(9;22) translocations.
Additional file 2: Supplementary Materials and Methods.
Additional file 3: Table S2. Differentially expressed genes between
CML cases with variant and classic t(9;22). Genes are rank-ordered
according to fold change value.
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